# | Title | Journal | Year | Citations |
---|
|
1 | Final Version of 2009 AJCC Melanoma Staging and Classification | Journal of Clinical Oncology | 2009 | 4,167 |
2 | Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification | Journal of Clinical Oncology | 2014 | 3,966 |
3 | One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States | Journal of Clinical Oncology | 2008 | 3,948 |
4 | Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes | Journal of Clinical Oncology | 2009 | 3,842 |
5 | Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer | Journal of Clinical Oncology | 2000 | 3,582 |
6 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group | Journal of Clinical Oncology | 2007 | 3,443 |
7 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update | Journal of Clinical Oncology | 2013 | 3,396 |
8 | Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group | Journal of Clinical Oncology | 2010 | 3,320 |
9 | Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas | Journal of Clinical Oncology | 1999 | 3,231 |
10 | Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients | Journal of Clinical Oncology | 2001 | 3,199 |
11 | Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World | Journal of Clinical Oncology | 2006 | 3,174 |
12 | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States | Journal of Clinical Oncology | 2011 | 3,145 |
13 | Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2008 | 3,068 |
14 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2008 | 3,049 |
15 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations | Journal of Clinical Oncology | 2013 | 2,911 |
16 | Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma | Journal of Clinical Oncology | 2003 | 2,831 |
17 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2003 | 2,830 |
18 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology | 2018 | 2,823 |
19 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study | Journal of Clinical Oncology | 2008 | 2,759 |
20 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study | Journal of Clinical Oncology | 2004 | 2,739 |
21 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer | Journal of Clinical Oncology | 2010 | 2,732 |
22 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates | Journal of Clinical Oncology | 2010 | 2,712 |
23 | Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis | Journal of Clinical Oncology | 2005 | 2,678 |
24 | Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease | Journal of Clinical Oncology | 1999 | 2,644 |
25 | Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma | Journal of Clinical Oncology | 2001 | 2,473 |
26 | International Staging System for Multiple Myeloma | Journal of Clinical Oncology | 2005 | 2,468 |
27 | How To Build and Interpret a Nomogram for Cancer Prognosis | Journal of Clinical Oncology | 2008 | 2,454 |
28 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer | Journal of Clinical Oncology | 2008 | 2,450 |
29 | Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System | Journal of Clinical Oncology | 2001 | 2,410 |
30 | Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer | Journal of Clinical Oncology | 2006 | 2,404 |
31 | Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy | Journal of Clinical Oncology | 2004 | 2,345 |
32 | Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Journal of Clinical Oncology | 2010 | 2,308 |
33 | Immune Checkpoint Blockade in Cancer Therapy | Journal of Clinical Oncology | 2015 | 2,303 |
34 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma | Journal of Clinical Oncology | 2009 | 2,249 |
35 | Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Journal of Clinical Oncology | 2004 | 2,202 |
36 | Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group | Journal of Clinical Oncology | 2008 | 2,197 |
37 | Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group | Journal of Clinical Oncology | 2009 | 2,195 |
38 | Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor | Journal of Clinical Oncology | 2003 | 2,181 |
39 | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Journal of Clinical Oncology | 2007 | 2,168 |
40 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes | Journal of Clinical Oncology | 2012 | 2,162 |
41 | A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2004 | 2,122 |
42 | Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy | Journal of Clinical Oncology | 2000 | 2,086 |
43 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Journal of Clinical Oncology | 2015 | 2,075 |
44 | Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix | Journal of Clinical Oncology | 2000 | 2,054 |
45 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab | Journal of Clinical Oncology | 2014 | 2,050 |
46 | Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index | Journal of Clinical Oncology | 2013 | 2,043 |
47 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma | Journal of Clinical Oncology | 2009 | 2,042 |
48 | Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study | Journal of Clinical Oncology | 2000 | 2,006 |
49 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer | Journal of Clinical Oncology | 2002 | 1,981 |
50 | Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial | Journal of Clinical Oncology | 2009 | 1,974 |